Disapproval from top shareholder throws $74bn BMS/Celgene merger into doubt

pharmafile | February 28, 2019 | News story | Sales and Marketing Bristol-Myers Squibb, Celgene, acquisition, pharma 

The news kicked off 2009 with a bang when Bristol-Myers Squibb announced it intended to acquire Celgene for $74 billion, but what could potentially be the biggest pharmaceutical industry merger of all time has been thrown into doubt thanks to a key BMS shareholder.

Top shareholder Wellington Management, which owns around 8% of BMS shares, has announced, in a rare move, that it does not support the prospective deal on the basis that it is a risky and expensive move. Celgene’s shares dropped by 8.5% following the news, but BMS shares rose 3% – the difference in share price between the two companies widened to almost 20%.

Activist hedge fund Starboard Value has been vocal in its opposition to the potential deal, canvassing its shareholders and filing a slate of nominees in a bid to put a stop to it. Analysts believe Wellington Management’s announcement could embolden this stance, and lead other shareholders to voice their disapproval for the deal.

However, BMS remained optimistic and determined: “We believe that we are acquiring Celgene at an attractive price, and that this transaction presents an important and unique opportunity to create sustainable value.”

Matt Fellows

Related Content

NICE approves first treatment for obstructive HCM for NHS use

The National Institute for Health and Care Excellence (NICE) has announced that it has approved …

Oncimmune Holdings sells businesses to Freenome in £13m deal

UK-based life sciences and immunodiagnostics firm Oncimmune Holdings has announced that it has sold its …

Sobi acquires CTI BioPharma Corporation for $1.7bn

Swedish Orphan Biovitrum, aka Sobi, has announced that it had entered into a ‘plan of …

Latest content